Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

• Published in: Clinical cancer research Vol. 25; no. 6; pp. 1718 - 1726
• Main Authors: Ramchandren, Radhakrishnan, Advani, Ranjana H., Ansell, Stephen M., Bartlett, Nancy L., Chen, Robert, Connors, Joseph M., Feldman, Tatyana, Forero-Torres, Andres, Friedberg, Jonathan W., Gopal, Ajay K., Gordon, Leo I., Kuruvilla, John, Savage, Kerry J., Younes, Anas, Engley, Gerald, Manley, Thomas J., Fenton, Keenan, Straus, David J.
• Format: Journal Article
• Language: English
• Published: United States 15.03.2019
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bleomycin - administration & dosage; Bleomycin - adverse effects; Brentuximab Vedotin - administration & dosage; Brentuximab Vedotin - adverse effects; Canada; Chemotherapy-Induced Febrile Neutropenia - epidemiology; Chemotherapy-Induced Febrile Neutropenia - etiology; Dacarbazine - administration & dosage; Dacarbazine - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Female; Follow-Up Studies; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin Disease - pathology; Humans; Kaplan-Meier Estimate; Lung Injury - chemically induced; Lung Injury - epidemiology; Male; Middle Aged; Neoplasm Staging; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; Progression-Free Survival; United States; Vinblastine - administration & dosage; Vinblastine - adverse effects; Canada; United States

To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin)...